Nurix Therapeutics (NRIX) Competitors

Nurix Therapeutics logo
$14.24 -0.49 (-3.33%)
Closing price 04:00 PM Eastern
Extended Trading
$14.53 +0.29 (+2.04%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NRIX vs. ORKA, IONS, GRAL, MIRM, and LGND

Should you buy Nurix Therapeutics stock or one of its competitors? Nurix Therapeutics's main competitors and comparable companies include Oruka Therapeutics (ORKA), Ionis Pharmaceuticals (IONS), GRAIL (GRAL), Mirum Pharmaceuticals (MIRM), and Ligand Pharmaceuticals (LGND). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nurix Therapeutics compare to Oruka Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Oruka Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nurix Therapeutics$83.98M18.52-$264.46M$2.316.16
Oruka TherapeuticsN/AN/A-$105.43M-$2.11N/A

Nurix Therapeutics currently has a consensus price target of $34.43, suggesting a potential upside of 141.77%. Oruka Therapeutics has a consensus price target of $141.80, suggesting a potential upside of 47.22%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Nurix Therapeutics is more favorable than Oruka Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nurix Therapeutics
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.87
Oruka Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80

Nurix Therapeutics has a net margin of 42.01% compared to Oruka Therapeutics' net margin of 0.00%. Nurix Therapeutics' return on equity of 49.34% beat Oruka Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Nurix Therapeutics42.01% 49.34% 38.61%
Oruka Therapeutics N/A -19.34%-18.74%

In the previous week, Oruka Therapeutics had 20 more articles in the media than Nurix Therapeutics. MarketBeat recorded 25 mentions for Oruka Therapeutics and 5 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.53 beat Oruka Therapeutics' score of 0.06 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nurix Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oruka Therapeutics
6 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Nurix Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, meaning that its share price is 134% less volatile than the broader market.

56.4% of Oruka Therapeutics shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Nurix Therapeutics beats Oruka Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Nurix Therapeutics compare to Ionis Pharmaceuticals?

Nurix Therapeutics (NASDAQ:NRIX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Nurix Therapeutics presently has a consensus price target of $34.43, suggesting a potential upside of 141.77%. Ionis Pharmaceuticals has a consensus price target of $75.71, suggesting a potential upside of 180.84%. Given Ionis Pharmaceuticals' higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Nurix Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nurix Therapeutics
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.87
Ionis Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.78

Nurix Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Nurix Therapeutics has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nurix Therapeutics$83.98M18.52-$264.46M$2.316.16
Ionis Pharmaceuticals$944M4.76-$381.39M-$3.32N/A

Nurix Therapeutics has a net margin of 42.01% compared to Ionis Pharmaceuticals' net margin of -56.98%. Nurix Therapeutics' return on equity of 49.34% beat Ionis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Nurix Therapeutics42.01% 49.34% 38.61%
Ionis Pharmaceuticals -56.98%-120.62%-16.99%

In the previous week, Ionis Pharmaceuticals had 21 more articles in the media than Nurix Therapeutics. MarketBeat recorded 26 mentions for Ionis Pharmaceuticals and 5 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.53 beat Ionis Pharmaceuticals' score of 0.22 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nurix Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ionis Pharmaceuticals
6 Very Positive mention(s)
4 Positive mention(s)
9 Neutral mention(s)
6 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Nurix Therapeutics beats Ionis Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Nurix Therapeutics compare to GRAIL?

Nurix Therapeutics (NASDAQ:NRIX) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Nurix Therapeutics presently has a consensus price target of $34.43, suggesting a potential upside of 141.77%. GRAIL has a consensus price target of $128.80, suggesting a potential upside of 21.65%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than GRAIL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nurix Therapeutics
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.87
GRAIL
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Nurix Therapeutics had 1 more articles in the media than GRAIL. MarketBeat recorded 5 mentions for Nurix Therapeutics and 4 mentions for GRAIL. GRAIL's average media sentiment score of 0.66 beat Nurix Therapeutics' score of 0.53 indicating that GRAIL is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nurix Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
GRAIL
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Nurix Therapeutics has a net margin of 42.01% compared to GRAIL's net margin of -243.80%. Nurix Therapeutics' return on equity of 49.34% beat GRAIL's return on equity.

Company Net Margins Return on Equity Return on Assets
Nurix Therapeutics42.01% 49.34% 38.61%
GRAIL -243.80%-16.13%-14.38%

Nurix Therapeutics has higher earnings, but lower revenue than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nurix Therapeutics$83.98M18.52-$264.46M$2.316.16
GRAIL$147.17M32.35-$408.35M-$9.50N/A

Nurix Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, GRAIL has a beta of 2.86, indicating that its share price is 186% more volatile than the broader market.

Summary

Nurix Therapeutics beats GRAIL on 9 of the 13 factors compared between the two stocks.

How does Nurix Therapeutics compare to Mirum Pharmaceuticals?

Nurix Therapeutics (NASDAQ:NRIX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Nurix Therapeutics presently has a consensus price target of $34.43, indicating a potential upside of 141.77%. Mirum Pharmaceuticals has a consensus price target of $155.56, indicating a potential upside of 69.18%. Given Nurix Therapeutics' higher possible upside, analysts plainly believe Nurix Therapeutics is more favorable than Mirum Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nurix Therapeutics
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.87
Mirum Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93

Mirum Pharmaceuticals has higher revenue and earnings than Nurix Therapeutics. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nurix Therapeutics$83.98M18.52-$264.46M$2.316.16
Mirum Pharmaceuticals$521.31M11.51-$23.36M-$15.47N/A

In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than Nurix Therapeutics. MarketBeat recorded 11 mentions for Mirum Pharmaceuticals and 5 mentions for Nurix Therapeutics. Mirum Pharmaceuticals' average media sentiment score of 0.70 beat Nurix Therapeutics' score of 0.53 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nurix Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mirum Pharmaceuticals
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Nurix Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

Nurix Therapeutics has a net margin of 42.01% compared to Mirum Pharmaceuticals' net margin of -134.75%. Nurix Therapeutics' return on equity of 49.34% beat Mirum Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Nurix Therapeutics42.01% 49.34% 38.61%
Mirum Pharmaceuticals -134.75%-97.25%-12.59%

Summary

Nurix Therapeutics beats Mirum Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Nurix Therapeutics compare to Ligand Pharmaceuticals?

Nurix Therapeutics (NASDAQ:NRIX) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Nurix Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Ligand Pharmaceuticals has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nurix Therapeutics$83.98M18.52-$264.46M$2.316.16
Ligand Pharmaceuticals$268.09M21.92$124.45M$2.24131.17

In the previous week, Ligand Pharmaceuticals had 11 more articles in the media than Nurix Therapeutics. MarketBeat recorded 16 mentions for Ligand Pharmaceuticals and 5 mentions for Nurix Therapeutics. Ligand Pharmaceuticals' average media sentiment score of 0.63 beat Nurix Therapeutics' score of 0.53 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nurix Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ligand Pharmaceuticals
7 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Nurix Therapeutics currently has a consensus target price of $34.43, indicating a potential upside of 141.77%. Ligand Pharmaceuticals has a consensus target price of $355.38, indicating a potential upside of 20.95%. Given Nurix Therapeutics' higher possible upside, equities analysts plainly believe Nurix Therapeutics is more favorable than Ligand Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nurix Therapeutics
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.87
Ligand Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

Nurix Therapeutics has a net margin of 42.01% compared to Ligand Pharmaceuticals' net margin of 20.27%. Nurix Therapeutics' return on equity of 49.34% beat Ligand Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Nurix Therapeutics42.01% 49.34% 38.61%
Ligand Pharmaceuticals 20.27%5.22%2.74%

Summary

Nurix Therapeutics and Ligand Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Nurix Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NRIX vs. The Competition

MetricNurix TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.61B$4.06B$7.82B$11.74B
Dividend YieldN/A3.63%2.47%4.46%
P/E Ratio6.1627.4232.3226.73
Price / Sales18.5216.068.565.71
Price / CashN/A22.9521.0121.90
Price / Book2.694.184.463.72
Net Income-$264.46M-$24.15M$3.52B$393.10M
7 Day Performance-10.33%-7.25%-5.47%-4.73%
1 Month Performance-41.69%-5.98%-4.57%-7.14%
1 Year Performance11.34%-7.72%-1.79%-7.51%

Nurix Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NRIX
Nurix Therapeutics
3.6859 of 5 stars
$14.24
-3.3%
$34.43
+141.8%
+15.1%$1.61B$83.98M6.16357
ORKA
Oruka Therapeutics
2.7469 of 5 stars
$104.56
+1.7%
$133.00
+27.2%
+266.5%$6.71BN/AN/A68
IONS
Ionis Pharmaceuticals
3.5748 of 5 stars
$31.00
-21.4%
$85.33
+175.3%
-60.9%$6.67B$944MN/A1,402
GRAL
GRAIL
2.5017 of 5 stars
$128.08
+5.5%
$128.80
+0.6%
+32.6%$6.42B$147.17MN/A910
MIRM
Mirum Pharmaceuticals
2.7919 of 5 stars
$93.18
-0.6%
$154.94
+66.3%
+28.2%$6.33B$521.31MN/A433

Related Companies and Tools


This page (NASDAQ:NRIX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners